Author:
Guzman Jaime,Oen Kiem,Huber Adam M,Watanabe Duffy Karen,Boire Gilles,Shiff Natalie,Berard Roberta A,Levy Deborah M,Stringer Elizabeth,Scuccimarri Rosie,Morishita Kimberly,Johnson Nicole,Cabral David A,Rosenberg Alan M,Larché Maggie,Dancey Paul,Petty Ross E,Laxer Ronald M,Silverman Earl,Miettunen Paivi,Chetaille Anne-Laure,Haddad Elie,Houghton Kristin,Spiegel Lynn,Turvey Stuart E,Schmeling Heinrike,Lang Bianca,Ellsworth Janet,Ramsey Suzanne E,Bruns Alessandra,Roth Johannes,Campillo Sarah,Benseler Susanne,Chédeville Gaëlle,Schneider Rayfel,Tse Shirley M L,Bolaria Roxana,Gross Katherine,Feldman Brian,Feldman Debbie,Cameron Bonnie,Jurencak Roman,Dorval Jean,LeBlanc Claire,St. Cyr Claire,Gibbon Michele,Yeung Rae S M,Duffy Ciarán M,Tucker Lori B
Abstract
ObjectiveTo describe probabilities and characteristics of disease flares in children with juvenile idiopathic arthritis (JIA) and to identify clinical features associated with an increased risk of flare.MethodsWe studied children in the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) prospective inception cohort. A flare was defined as a recurrence of disease manifestations after attaining inactive disease and was called significant if it required intensification of treatment. Probability of first flare was calculated with Kaplan–Meier methods, and associated features were identified using Cox regression.Results1146 children were followed up a median of 24 months after attaining inactive disease. We observed 627 first flares (54.7% of patients) with median active joint count of 1, physician global assessment (PGA) of 12 mm and duration of 27 weeks. Within a year after attaining inactive disease, the probability of flare was 42.5% (95% CI 39% to 46%) for any flare and 26.6% (24% to 30%) for a significant flare. Within a year after stopping treatment, it was 31.7% (28% to 36%) and 25.0% (21% to 29%), respectively. A maximum PGA >30 mm, maximum active joint count >4, rheumatoid factor (RF)-positive polyarthritis, antinuclear antibodies (ANA) and receiving disease-modifying antirheumatic drugs (DMARDs) or biological agents before attaining inactive disease were associated with increased risk of flare. Systemic JIA was associated with the lowest risk of flare.ConclusionsIn this real-practice JIA cohort, flares were frequent, usually involved a few swollen joints for an average of 6 months and 60% led to treatment intensification. Children with a severe disease course had an increased risk of flare.
Subject
General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology